Therefore, STAT3 is an intriguing target molecule for cancer treatment by suppressing antiapoptotic Bcl-2 family gene transcription through inhibition of JAK/STAT3/Bcl-2/Bcl-xL survival pathway employing niclosamide. This evidence concerns the gene BCL2L1 and cancer.